Largest provider of biopharmaceutical development and commercial outsourcing services.

Learn More About Quintiles

Highly selective medicines for genomically defined cancers.

Aisling congratulates the management team of Loxo on its recent acquisition by Eli Lilly.

Learn More About Loxo

Developing late-stage neuroscience compounds targeting migraine and psychiatric disorders.

Learn More About Biohaven

Novel treatments for people living with narcolepsy and other central nervous system disorders.

Learn More About Harmony

CoolSculpting®: more science, less fat.

Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.

Learn More About ZELTIQ

Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy

Learn More About Aimmune

Aimmune

Loxo

Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

Learn More

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

Learn More

Latest News

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

November 18, 2024

Wayne, PA -- November 18, 2024 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has...

Aclaris Therapeutics Announces $80 Million Private Placement

November 18, 2024

Wayne, PA -- November 18, 2024 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today...

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

November 18, 2024

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – – Syndax...

more news